820 related articles for article (PubMed ID: 21549414)
1. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells.
Yin ZJ; Jin FG; Liu TG; Fu EQ; Xie YH; Sun RL
J Surg Res; 2011 Dec; 171(2):675-83. PubMed ID: 20605584
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
Su L; Wang Y; Xiao M; Lin Y; Yu L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
5. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
6. Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC.
Luo YQ; Ming Z; Zhao L; Yao LJ; Dong H; Du JP; Wu SZ; Hu W
IUBMB Life; 2012 May; 64(5):423-31. PubMed ID: 22473740
[TBL] [Abstract][Full Text] [Related]
7. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Zhao M; Gao FH; Wang JY; Liu F; Yuan HH; Zhang WY; Jiang B
Lung Cancer; 2011 Sep; 73(3):366-74. PubMed ID: 21333372
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
9. [Effects of JAK2/STAT3 signaling pathway on angiogenesis in non-small cell lung cancer].
Zhao M; Liu F; Wang JY; Zhang WY; Gao FH; Jiang B
Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):375-81. PubMed ID: 21418908
[TBL] [Abstract][Full Text] [Related]
10. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
11. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
12. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
13. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
15. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
Chen P; Li J; Ge LP; Dai CH; Li XQ
Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
[TBL] [Abstract][Full Text] [Related]
17. Expression of transcription factor Pokemon in non-small cell lung cancer and its clinical significance.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Fu K; Zhang J
Chin Med J (Engl); 2008 Mar; 121(5):445-9. PubMed ID: 18364119
[TBL] [Abstract][Full Text] [Related]
18. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
19. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
Wang R; Geng J; Wang JH; Chu XY; Geng HC; Chen LB
Lung Cancer; 2009 Nov; 66(2):237-44. PubMed ID: 19261348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
